Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Am Heart J. 2014 Apr 18;168(2):160–167. doi: 10.1016/j.ahj.2014.04.005

Table I.

Inclusion and exclusion criteria

Inclusion criteria Exclusion criteria
• Age ≥21 y • Anticipated life expectancy <6 mo
• Electrocardiographically confirmed AF • Atrial flutter only without AF
• ≥1 of the following:

  • New-onset AF within the previous 6 mo

  • Initiation or transition to a non–vitamin K oral anticoagulant within the previous 3 mo*

 • Transient AF secondary to a reversible condition (eg, hyperthyroidism, pulmonary embolism, and postcardiothoracic surgery)
• Anticipated, regular semiannual follow-up outpatient visits • Participation in a randomized clinical study of any anticoagulation for AF
• Signed informed consent • Any participation in the ORBIT-AF I registry
*

Including dabigatran, rivaroxaban, and apixaban. If additional agents are approved during the study period, they will be added.